vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Eightco Holdings Inc. (ORBS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $10.2M, roughly 1.9× Eightco Holdings Inc.). NewAmsterdam Pharma Co N.V. runs the higher net margin — -90.7% vs -2281.6%, a 2190.9% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -49.9%). Eightco Holdings Inc. produced more free cash flow last quarter ($-11.0M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
NAMS vs ORBS — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $10.2M |
| Net Profit | $-17.4M | $-232.5M |
| Gross Margin | — | -13.0% |
| Operating Margin | -186.1% | -475.0% |
| Net Margin | -90.7% | -2281.6% |
| Revenue YoY | 740.1% | -49.9% |
| Net Profit YoY | 55.5% | -9183.3% |
| EPS (diluted) | $-0.15 | $-2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | $19.1M | $7.6M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | $12.8M | $20.3M | ||
| Q3 24 | $29.1M | $6.1M | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | $8.0M |
| Q4 25 | — | $-232.5M | ||
| Q3 25 | — | $-25.8M | ||
| Q2 25 | $-17.4M | $-1.2M | ||
| Q1 25 | — | $-2.5M | ||
| Q4 24 | $-92.2M | $-2.5M | ||
| Q3 24 | $-16.6M | $-3.2M | ||
| Q2 24 | — | $4.4M | ||
| Q1 24 | — | $1.9M |
| Q4 25 | — | -13.0% | ||
| Q3 25 | — | -3.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 25.1% | ||
| Q1 24 | — | 17.5% |
| Q4 25 | — | -475.0% | ||
| Q3 25 | — | -116.9% | ||
| Q2 25 | -186.1% | -15.9% | ||
| Q1 25 | — | -14.3% | ||
| Q4 24 | -338.5% | -11.9% | ||
| Q3 24 | -85.9% | -29.1% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | — | -39.6% |
| Q4 25 | — | -2281.6% | ||
| Q3 25 | — | -487.6% | ||
| Q2 25 | -90.7% | -15.4% | ||
| Q1 25 | — | -25.7% | ||
| Q4 24 | -721.7% | -12.3% | ||
| Q3 24 | -57.2% | -52.5% | ||
| Q2 24 | — | 84.2% | ||
| Q1 24 | — | 24.4% |
| Q4 25 | — | $-2.34 | ||
| Q3 25 | — | $-0.58 | ||
| Q2 25 | $-0.15 | $-0.38 | ||
| Q1 25 | — | $-0.84 | ||
| Q4 24 | $-0.91 | $-1.44 | ||
| Q3 24 | $-0.18 | $-1.77 | ||
| Q2 24 | — | $2.15 | ||
| Q1 24 | — | $1.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $58.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $232.6M |
| Total Assets | $815.1M | $250.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $58.5M | ||
| Q3 25 | — | $23.7M | ||
| Q2 25 | $739.2M | $696.3K | ||
| Q1 25 | — | $434.4K | ||
| Q4 24 | $834.2M | $239.2K | ||
| Q3 24 | $422.7M | $2.4M | ||
| Q2 24 | — | $363.1K | ||
| Q1 24 | — | $808.8K |
| Q4 25 | — | $232.6M | ||
| Q3 25 | — | $339.2M | ||
| Q2 25 | $778.5M | $8.9M | ||
| Q1 25 | — | $9.7M | ||
| Q4 24 | $757.5M | $11.9M | ||
| Q3 24 | $378.9M | $13.0M | ||
| Q2 24 | — | $13.8M | ||
| Q1 24 | — | $3.9M |
| Q4 25 | — | $250.2M | ||
| Q3 25 | — | $355.5M | ||
| Q2 25 | $815.1M | $48.7M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | $864.6M | $50.8M | ||
| Q3 24 | $439.2M | $49.2M | ||
| Q2 24 | — | $48.4M | ||
| Q1 24 | — | $50.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-11.0M |
| Free Cash FlowOCF − Capex | $-37.8M | $-11.0M |
| FCF MarginFCF / Revenue | -197.2% | -107.7% |
| Capex IntensityCapex / Revenue | 0.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | $-37.7M | $-659.2K | ||
| Q1 25 | — | $999.8K | ||
| Q4 24 | $-37.5M | $-6.6M | ||
| Q3 24 | $-12.5M | $77.7K | ||
| Q2 24 | — | $-440.3K | ||
| Q1 24 | — | $-723.3K |
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-37.8M | $-661.3K | ||
| Q1 25 | — | $999.7K | ||
| Q4 24 | $-37.5M | $-6.6M | ||
| Q3 24 | $-12.6M | $73.0K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -107.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | -197.2% | -8.7% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | -293.5% | -32.7% | ||
| Q3 24 | -43.2% | 1.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.5% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.10× | ||
| Q1 24 | — | -0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
